What is the catalog number for HXR9?

The catalog number for HXR9 is HY-P3245.

What sizes are available for HXR9?

HXR9 is available in the following size(s): 1 Each.

HXR9 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures HXR9?

HXR9 is manufactured by QuantiMol.

What is the estimated delivery time for HXR9?

Estimated delivery time for HXR9 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for HXR9?

The safety data sheet for HXR9 is available here: http://file.medchemexpress.com/batch_PDF/HY-P3245/.

HXR9

HXR9 is a cell-permeable peptide and a competitive antagonist of HOX/PBX interaction. HXR9 antagonizes the interaction between HOX and a second transcrip-tion factor (PBX), which binds to HOX proteins in paralogue groups1 to 8. HXR9 selectively decreases cell proliferation and promotes apoptosis in cells with a high level of expression of the HOXA/PBX3 genes, such as MLL-rearranged leukemic cells[1][2][3].

Product Specifications

CAS Number

917953-08-3

UNSPSC

12352209

Target

Apoptosis

Type

Peptides

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/hxr9.html

Solubility

10 mM in DMSO

Smiles

O=C([C@H]1N(CCC1)C([C@@H](NC([C@@H](N)CC2=CNC3=CC=CC=C23)=O)CC4=CC=C(C=C4)O)=O)N[C@H](C(N[C@@H](CCSC)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@H](C(N[C@H](C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(O)=O)CCCNC(N)=N)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC5=CN=CN5)=O)CC6=CN=CN6)=O)=O)=O)=O)CC7=CNC8=CC=CC=C78

Molecular Formula

C119H193N53O20S

Molecular Weight

2718.21

References & Citations

[1]Morgan R, et al. Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma. Cancer Res. 2007;67 (12) :5806-5813.|[2]Li Z, et al. PBX3 is an important cofactor of HOXA9 in leukemogenesis. Blood. 2013;121 (8) :1422-1431.|[3]Plowright L, et al. HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer) . Br J Cancer. 2009;100 (3) :470-475.